Ab­b­Vie taps Jen­nifer Doud­na start­up for li­cens­ing deal worth up to $300M for 2 'off-the-shelf' CRISPR-edit­ed CAR-Ts

“Off-the-shelf” CAR-Ts have emerged as a hot-tick­et tar­get in next-gen on­col­o­gy R&D, with Big Phar­mas plac­ing big down pay­ments on nov­el tech. Now, a Cal­i­for­nia …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER